

Notes

- Not Exhaustive
- Position within Phase does not imply proximity to next phase
- Position represents highest development stage for each asset
- Based on publicly available information


As of January 31st, 2024

Cell Therapy Landscape Chart

Legend

Approach	TCR	CAR-T	CAR-NK / NK cell	TIL / MIL / PBL	γδ T-cell	Other
Autologous						
Allogeneic						

- (1) Searching for strategic alternatives
(2) Acquired Ph1 assets from Cellular Biomedicines
(3) Acquired cell therapy assets from 2seventybio (formerly bluebird)
(4) Approved in EU; Registration in US
(5) New donor source for allogeneic stem cell transplant



@andrewpannu
Andrew Pannu